OCA Ventures
VC Fund
Chicago, United States
OCA Ventures is a VC fund in Chicago focused on Software and Health Care. We're an early stage venture capital firm focused on equity investments in companies with dramatic growth potential, primarily in technology and highly-scalable services businesses. Our focus investment areas are digital health, fintech, consumer software, and enterprise software.
- Total investments:
- 155
- Last investment:
- Lead investor:
- 22%
- Fund size:
- $84M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries OCA Ventures invests in
Stages OCA Ventures invests in
Countries OCA Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.1M–$5M
- Series A
- $2.3M–$11M
- Series B
- $5M–$40M
Investment Focus
Industry
- Software 26 (17%)
- Health Care 25 (16%)
- SaaS 12 (8%)
- Artificial Intelligence 12 (8%)
- Analytics 9 (6%)
Stage
- Series A 43 (28%)
- Seed 42 (27%)
- Series B 19 (12%)
- Series C 10 (6%)
- Funding Round 8 (5%)
Country
- United States 82 (53%)
- United Kingdom 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bob Saunders
General Partner
|
General Partner | Total investments: 14 | Find email | |
Ian Drury
Venture Partner
|
Venture Partner | Total investments: 3 | Find email | |
Jim Dugan
CEO, Co-Founder, and Founding Managing Partner
|
CEO, Co-Founder, and Founding Managing Partner | Total investments: 17 | Find email | |
John Dugan
Chairman Emeritus & Co-Founder
|
Chairman Emeritus & Co-Founder | Total investments: 0 | Find email | |
Dana Sun
Senior Associate
|
Senior Associate | Total investments: 0 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Amplified Sciences
|
Amplified Sciences is a molecular diagnostics company unlike other diagnostics companies due to their ultra-sensitive molecular sensing technology with composition of matter IP exclusively licensed from Purdue University. The technology is disease state agnostic, can detect to the single molecule level, scales easily to point of care, and providesa very favorable cost structure for their platform of reagents. The first application – early detection of pancreatic cancer - is an assay that will quickly prove the investment thesis due to large unmet medical need and a favorable reimbursement path. The team has delivered a working prototype and published proof of concept data. | $2.6M / Seed / Nov 25, 2024 | |
GrayMatter Robotics
|
GrayMatter Robotics is a company that solves the most difficult surface treatment and finishing challenges faced by high-mix, high-variability manufacturers. They offer advanced robotics and proprietary AI technologies, designed into smart robotic cells that assist humans in tedious and ergonomically challenging tasks. | $45M / Series B / Jun 20, 2024 | |
Ocient
|
Ocient is a startup building a near-real-time database and data analytics platform for petabyte- to exabyte-scale data sets. Ocient was founded by the talent behind the largest software startup exit in Chicago’s history. Ocient is a well-funded company, with an engineering team comprised of brilliant computer scientists hailing from the world’s topuniversities and organizations. | $49.4M / Series B / Mar 11, 2024 | |
Balto
|
Balto unites agents and supervisors with AI to power better agent performance. Agents and managers trust Balto's real-time guidance to prevent missed sales opportunities, costly compliance mistakes, and negative customer experiences. Empowering agents results in happier customers, increased revenue, and better retention. Today, Balto hasguided over 150 million calls, provided over 185 million real-time recommendations, driven millions in increased revenue, and has a 4.8-star rating on G2.Balto is trusted by top contact centers, including National General Insurance, eHealth, American Homes for Rent, Spring Venture Group, and Cellular Sales. Want to learn more? Visit https://balto.ai. | $5.7M / Series B / Mar 05, 2024 | |
Buddy
|
Buddy is an on-demand insurance for an active, outdoor lifestyle. | $7M / Venture - Series Unknown / Jan 16, 2024 | |
Pair Team
|
Pair Team is on a mission to build the primary care infrastructure for America’s most vulnerable communities.They are the first tech-enabled care team that empowers safety-net primary care systems and the Medicaid & Medicare patients they serve. They act as an extension of the clinical staff to provide a personalized, high-touch careexperience while addressing patients' barriers to care such as lack of transportation, housing/food insecurity, and mobile phone access. Internally, they are building a unique care delivery platform to ensure clinical best practices, integrate care with community-based organizations, and automate administrative work so that clinicians can focus on time with our patients. | $9M / Series A / Oct 19, 2023 | |
Atalan
|
Atalan develops a clinician wellness risk management software to help predict and address clinician burnout and turnover, using machine learning and labor economics. Atalan helps healthcare organizations to make more effective risk management decisions on clinician wellness. The company was founded in 2021 and is based in Boston, USA. | $2.5M / Seed / Oct 05, 2023 | |
AMOpportunities
|
AMOpportunities connects international medical students and graduates with U.S. physicians and institutions for clinical experiences. The company's platform offers individuals the opportunity to explore and apply for clinical experiences at 200+ clinical sites across 70+ medical specialties and subspecialties. AMO provides exceptionalsupport services such as visa and housing assistance.It was founded in 2013 and based in Chicago, Illinois. | $2M / Series A / Aug 02, 2023 | |
RecruitBot
|
RecruitBot is recruiting agency software. They use the power of big data and machine learning for recruiting. They engage in automating conversations with class email marketing tools. | $8.2M / Seed / Jul 11, 2023 | |
Alnair Therapeutics
|
Alnair Therapeutics is a preclinical stage precision oncology platform focusing on developing innovative approaches to treat difficult-to-treat malignancies. It has created a first-of-its-kind drug delivery technology that uses the unique features of cancer metabolism to improve drug targeting and penetration directly into cancer cells, henceenhancing patient treatment outcomes. | $1M / Pre-Seed / Jun 30, 2023 | |
| See all 155 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does OCA Ventures invest in?
OCA Ventures invests primarily in Software, Health Care and SaaS startups, most often at Series A and Seed stage. Most of the 155 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is OCA Ventures's check size?
OCA Ventures typically joins rounds of $1.1M–$5M at Seed, $2.3M–$11M at Series A and $5M–$40M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds OCA Ventures participates in.
How do I contact OCA Ventures?
Public channels for OCA Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at OCA Ventures?
The team at OCA Ventures includes Bob Saunders (General Partner), Ian Drury (Venture Partner) and Jim Dugan (CEO, Co-Founder, and Founding Managing Partner), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
